| Document |
Document Title |
|
WO/2024/080441A1 |
The present invention provides: a Paracoccus aminovorans BM109 strain (accession number KCTC 15059BP), which is excellent for removing trimethylamine (TMA) or trimethylamine N-oxide (TMAO); and a pharmaceutical composition for preventing...
|
|
WO/2024/079471A1 |
A prebiotic oligosaccharide composition for use in reducing the level of ammonia. The composition comprises oligosaccharide compounds, for example galactooligosaccharide compounds, which includes: (a) at least 8 wt% Gal-(β1-3)-Gal-(β1-...
|
|
WO/2024/080323A1 |
Provided is a novel use of a composition that contains a prescribed sulfur-containing compound, a salt thereof, or both. The present invention is a sirtuin activator or expression enhancer, a NAD+ increasing agent, or a senescent cell in...
|
|
WO/2024/079324A1 |
The present invention relates to a composition for use in the treatment of a disease or disorder, wherein said disease or disorder is preferably a disease or disorder in which aldosterone overexposure contributes to the symptoms of said ...
|
|
WO/2024/077987A1 |
The present invention relates to the field of medicine. Specifically, disclosed is a PRDX1 IgG neutralizing antibody, which is a monoclonal neutralizing antibody against a PRDX1 protein or a polyclonal neutralizing antibody against the P...
|
|
WO/2024/079524A1 |
Provided herein are compositions and methods for treating kidney disease, for example diabetic kidney disease, using compositions comprising SDC2+ stromal stem cells.
|
|
WO/2024/077488A1 |
Use of a polygonum capitatum granular preparation in the preparation of drugs for clearing heat and promoting diuresis, inducing diuresis for treating stranguria, treating urinary tract infection or stones, treating pyelonephritis, detox...
|
|
WO/2024/077489A1 |
The use of a Polygonum capitatum Buch-Ham ex D. Don extract in the preparation of Relinqing granules for clearing heat and removing dampness, inducing diuresis for treating strangurtia, treating urinary system infections or stones, treat...
|
|
WO/2024/079331A1 |
The invention relates to the field of drug delivery for inflammatory diseases, more specifically inflammatory kidney, eye, lung, and intestinal diseases, and kidney, eye, lung and intestinal diseases in general.
|
|
WO/2024/080777A1 |
The present invention provides a pharmaceutical composition advantageously useful for preventing or treating nephritis.
|
|
WO/2024/077490A1 |
A method for improving the quality of a Polygonum capitatum extract and quality of Relinqing granules, said method comprising the following steps: (1) adding ethanol to a dry product of the overground part of a Polygonum capitatum medici...
|
|
WO/2024/074116A1 |
The present invention relates to use of a compound represented by formula (I) or an ester thereof or a pharmaceutically acceptable salt thereof in the treatment of a disease accompanied by fibrosis.
|
|
WO/2024/074105A1 |
The present invention belongs to the field of biopharmaceuticals. Provided in the present invention are keratin YK93-4, a nucleic acid molecule encoding same, an expression vector containing the nucleic acid molecule, a host cell contain...
|
|
WO/2024/074102A1 |
The present invention pertains to the field of biopharmaceuticals and provides a keratin YK93-6, a nucleic acid molecule encoding same, an expression vector comprising the nucleic acid molecule, a host cell that contains the expression v...
|
|
WO/2024/074107A1 |
The present invention belongs to the field of biopharmaceuticals. Provided are a keratin YK93-2, a nucleic acid molecule encoding the same, an expression vector comprising the nucleic acid molecule, a host cell comprising the expression ...
|
|
WO/2024/074111A1 |
The present invention pertains to the field of biopharmaceuticals and provides a keratin YK93-9, a nucleic acid molecule encoding same, an expression vector comprising the nucleic acid molecule, a host cell that contains the expression v...
|
|
WO/2024/074110A1 |
The present invention relates to the field of biological pharmacy, provides keratin YK93-5, a nucleic acid molecule encoding same, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or...
|
|
WO/2024/075139A1 |
The present application relates to an improved process for the preparation of finerenone and intermediates thereof, which is represented by the following structural formula-I.
|
|
WO/2024/074104A1 |
The present invention belongs to the field of biopharmaceuticals. Provided in the present invention are keratin YK93-8, a nucleic acid molecule encoding same, an expression vector containing the nucleic acid molecule, a host cell contain...
|
|
WO/2024/076177A1 |
The present invention relates to a pharmaceutical composition comprising enavogliflozin as an active ingredient for the prevention or treatment of diabetes and/or renal diseases in patients who have or are at risk of diabetes and/or rena...
|
|
WO/2024/069191A1 |
The present invention provides a method of treating a patient suffering from bladder pain syndrome, said method comprising administering a solution containing a clostridial neurotoxin into the bladder of the patient; increasing the volum...
|
|
WO/2024/067756A1 |
The present invention relates to a drug, a dosage scheme, an administration interval, and an administration mode for treating membranous nephropathy with a TACI-Fc fusion protein. Results show that the TACI-Fc fusion protein provided by ...
|
|
WO/2024/071039A1 |
The present disclosure provides a pharmaceutical composition for treating or preventing T cell-related disorders, the pharmaceutical composition containing induced regulatory T cells having high functionality and a stable immunosuppressi...
|
|
WO/2024/068808A1 |
A composition comprises at least two ingredients selected from the group consisting of: Fish oil, L-arginine, Vitamin E, Vitamin C, Vitamin B3, Vitamin B5, Vitamin B6, Vitamin B1, Vitamin B2, Folic acid, Biotin, Vitamin B12, and is formu...
|
|
WO/2024/072421A1 |
Disclosed herein are oral formulations for treating, preventing, or ameliorating symptoms associated with bacterial vaginosis or yeast infections. The oral formulations disclosed herein comprise a probiotic composition and a supplement c...
|
|
WO/2024/073056A1 |
A pharmaceutical formulation for treating a patient with an elevated serum level of an intestinal microbial metabolite includes an effective amount of cucurbituril. A method of treating a patient with an elevated serum level of an intest...
|
|
WO/2024/073672A1 |
The present disclosure relates to methods of treating a kidney disease or disorder, including methods comprising administering sparsentan and a SGLT2 inhibitor to a subject in need thereof.
|
|
WO/2024/068524A1 |
The present invention relates to methods for treating bacterial prostatitis, which comprises administration of gepotidacin or pharmaceutically acceptable salts thereof to a human in need thereof.
|
|
WO/2024/072798A1 |
Provided herein are methods of preparing a human patient for surgery (e.g., cardiac surgery with cardiopulmonary bypass (CPB)) in a particular sub-population (e.g., a human patient with kidney disease, including chronic kidney disease (C...
|
|
WO/2024/062164A1 |
The invention relates to sagerinic acid and the compositions containing it, for use in the prevention and/or treatment of disorders related to senescence in humans and animals.
|
|
WO/2024/064612A1 |
The present application concerns selected engineered analogs of atrial natriuretic peptides, compositions that contain these peptides and uses thereof to treat, prevent, or alleviate the symptoms of cardiovascular, cardiorenal, or metabo...
|
|
WO/2024/062405A1 |
The present invention relates to thyroid hormones or their salts for the use in the treatment of autosomal dominant polycystic kidney disease.
|
|
WO/2024/061371A1 |
Provided is a small-molecule steroid synthetase inhibitor. Further provided is use of the steroid synthetase inhibitors.
|
|
WO/2024/061202A1 |
The present disclosure relates to a double-stranded ribonucleic acid (RNA) for inhibiting HMGB1 gene expression, and a modifier, conjugate and use thereof. Specifically, the present disclosure relates to a double-stranded RNA for inhibit...
|
|
WO/2024/063734A1 |
The present invention relates to a film coated tablet comprising mirabegron, polyethylene oxide and at least one pharmaceutically acceptable excipient wherein the weight ratio of polyethylene oxide to mirabegron ranges from 1 :1 to 4:1 s...
|
|
WO/2024/056498A1 |
The present invention relates to a compound having general Formula (I), (I), (e.g., oxindole alkaloid or its derivatives; (e.g., rotundifoline and rhynchophylline (compounds 1 and 2) or their derivatives or analogues thereof) for use as ...
|
|
WO/2023/213211A9 |
Disclosed herein is a 2,4-disubstituted-5-fluoropyrimidine derivative having a structural general formula represented by formula I: wherein, R1 and R2 are each independently selected from: R4 is selected from: Also disclosed herein is a ...
|
|
WO/2024/053812A1 |
Provided are a method of treating chronic kidney disease or one or more symptoms thereof, or reducing a complication related to chronic kidney disease, the method comprising, administering a therapeutically effective amount of gamma-cycl...
|
|
WO/2024/052350A1 |
Autosomal dominant polycystic kidney disease (ADPKD) is a hereditary disease affecting 1 in 1,000 to 1 in 2,500 individuals worldwide. The inventor's study performed in 6 patients with ADPKD supports the hypothesis that the stimulation o...
|
|
WO/2024/051650A1 |
Use of a mulberry extract in the preparation of a product for preventing and/or treating chronic kidney disease. The mulberry extract can improve renal function indexes of ZDF rats, improve serum oxidation/nitrification stress and inflam...
|
|
WO/2024/047073A1 |
The invention relates to new toxin-binders for hemodialysis. The invention relates to an apoferritin nanoparticle for use as a toxin-binder in hemodialysis. The apoferritin nanoparticle comprises apoferritin subunits that, when combined ...
|
|
WO/2023/160569A9 |
This disclosure relates to compounds of Formula (I) as PGE2 receptor antagonists or a pharmaceutically acceptable salt thereof.
|
|
WO/2024/046340A1 |
Provided are a pharmaceutical composition and use thereof. The pharmaceutical composition comprises a component A and a component B. The component A comprises a polyphenol substance having 6-14 carbon atoms and/or can be metabolized in a...
|
|
WO/2024/047130A1 |
Relaxin-2 for use as a broad-spectrum substitute of glucocorticoids, mineralocorticoids, corticosteroids and their analogues for treating tissue and endothelial injuries without incurring inducing gluconeogenesis, Cushing's syndrome and ...
|
|
WO/2024/046323A1 |
Provided are benzo five-membered nitrogen ring compounds, a preparation method therefor, and the medical uses thereof. Specifically provided are: benzo five-membered nitrogen ring compounds, or pharmaceutically acceptable salts, isomers,...
|
|
WO/2024/045071A1 |
The present invention provides use of epidermal growth factor in preparing a medicament for treating interstitial cystitis. According to the present invention, epidermal growth factor (EGF) can be used to establish an interstitial cystit...
|
|
WO/2024/048683A1 |
The present invention provides a novel substance that suitably functions as an Met agonist. The present invention provides an artificial protein that includes an antibody Fc region, where an amino acid represented by SEQ ID NO: 1 is inse...
|
|
WO/2024/048748A1 |
The present invention provides an agent for inhibiting the progression of uremia in felids with severe renal failure, said agent containing an apoptosis inhibitor of macrophage (AIM), an AIM fragment having the biological activity of the...
|
|
WO/2024/049227A1 |
The present invention relates to a composition for preventing or treating lupus or glomerulonephritis, comprising a recombinant stabilized galectin 9 protein. Specifically, it was confirmed that the recombinant stabilized galectin 9 prot...
|
|
WO/2024/047574A1 |
A pharmaceutical composition comprising: (a) one or more of a first pellet comprising i. a first core, and ii. a first coating on the first core, wherein the first coating comprises a mineralocorticoid receptor (MR) modulator and a first...
|
